Pawel Robak
Overview
Explore the profile of Pawel Robak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
965
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mikulski D, Kedzior M, Mirocha G, Jerzmanowska-Piechota K, Witas Z, Wozniak L, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518146
Background: Daratumumab (Dara) is the first monoclonal antibody introduced into clinical practice to treat multiple myeloma (MM). It currently forms the backbone of therapy regimens in both newly diagnosed (ND)...
2.
Witkowska M, Majchrzak A, Robak P, Wolska-Washer A, Robak T
Expert Opin Biol Ther
. 2024 Oct;
24(11):1233-1244.
PMID: 39364800
Introduction: Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adult patients. The landscape of CLL therapy has changed in the last decades with the...
3.
Robak T, Witkowska M, Wolska-Washer A, Robak P
Expert Rev Hematol
. 2024 Oct;
17(11):781-796.
PMID: 39359174
Introduction: In the last decade, BTK inhibitors and the BCL-2 inhibitor venetoclax have replaced immunochemotherapy in the treatment of CLL. Areas Covered: This review describes the use of BTK inhibitors...
4.
Facon T, Dimopoulos M, Leleu X, Beksac M, Pour L, Hajek R, et al.
N Engl J Med
. 2024 Jun;
391(17):1597-1609.
PMID: 38832972
Background: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the...
5.
Dimopoulos M, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al.
N Engl J Med
. 2024 Jun;
391(5):408-421.
PMID: 38828951
Background: Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse....
6.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho P, et al.
N Engl J Med
. 2024 Jun;
391(5):393-407.
PMID: 38828933
Background: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies. Methods: In...
7.
Kubicki T, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek A, et al.
Pol Arch Intern Med
. 2024 May;
134(5).
PMID: 38747414
No abstract available.
8.
Kubicki T, Dytfeld D, Barnidge D, Sakrikar D, Przybylowicz-Chalecka A, Jamroziak K, et al.
Blood
. 2024 May;
144(9):955-963.
PMID: 38713888
Mass spectrometry (MS) can detect multiple myeloma-derived monoclonal proteins in the peripheral blood (PB) with high sensitivity, potentially serving as a PB assay for measurable residual disease (MRD). This study...
9.
Robak T, Braun M, Guminska A, Iskierka-Jazdzewska E, Robak P
Leuk Lymphoma
. 2024 Apr;
65(8):1175-1180.
PMID: 38608253
No abstract available.
10.
Wolska-Washer A, Robak P, Witkowska M, Robak T
Expert Opin Drug Metab Toxicol
. 2024 Mar;
20(4):207-224.
PMID: 38516702
Introduction: Bruton tyrosine kinase inhibitors (BTKi) have been used for the management of human diseases since the approval of the first-in class agent, ibrutinib, by the Food and Drug Administration...